HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thomas R Malek Selected Research

N(1)-methyl-2-lysergic acid diethylamide (MIL)

4/2021Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity.
1/2021Mouse IL-2/CD25 Fusion Protein Induces Regulatory T Cell Expansion and Immune Suppression in Preclinical Models of Systemic Lupus Erythematosus.
1/2021High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4+ and CD8+ neoantigen-specific T cells to promote antitumor immunity.
12/2020Acute Lipopolysaccharide-Induced Inflammation Lowers IL-2R Signaling and the Proliferative Potential of Regulatory T Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Thomas R Malek Research Topics

Disease

9Neoplasms (Cancer)
10/2022 - 07/2003
5Autoimmune Diseases (Autoimmune Disease)
12/2020 - 01/2003
5Type 1 Diabetes Mellitus (Autoimmune Diabetes)
11/2020 - 04/2015
2Melanoma (Melanoma, Malignant)
04/2021 - 01/2021
1Proteinuria
01/2021
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2021
1Lupus Nephritis
01/2021
1Inflammation (Inflammations)
12/2020
1Mitochondrial Diseases (Mitochondrial Disease)
01/2019
1Vasculitis (Vasculitides)
04/2015
1Opportunistic Infections (Opportunistic Infection)
05/2014
1Lymphoma (Lymphomas)
05/2014
1Pneumonia (Pneumonitis)
10/2010
1Asthma (Bronchial Asthma)
10/2010
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
01/2003
1Vaccinia
01/2003

Drug/Important Bio-Agent (IBA)

11Interleukin-2 (IL2)IBA
10/2022 - 01/2003
4CytokinesIBA
10/2022 - 01/2003
4N(1)-methyl-2-lysergic acid diethylamide (MIL)IBA
04/2021 - 12/2020
4VaccinesIBA
01/2021 - 07/2003
2Neoplasm Antigens (Tumor Antigens)IBA
04/2021 - 04/2008
2Proteins (Proteins, Gene)FDA Link
04/2021 - 01/2021
2AntigensIBA
01/2021 - 07/2003
2Interleukin-2 Receptors (IL 2 Receptor)IBA
01/2021 - 12/2017
1Cancer VaccinesIBA
01/2022
1Therapeutic UsesIBA
04/2021
1AutoantibodiesIBA
01/2021
1tyrosinase-related protein-1IBA
01/2021
1LipopolysaccharidesIBA
12/2020
1EnzymesIBA
01/2019
1CholesterolIBA
01/2019
1LipidsIBA
01/2019
1Heat-Shock Proteins (Heat-Shock Protein)IBA
05/2014
1Small Interfering RNA (siRNA)IBA
01/2014
1Mechanistic Target of Rapamycin Complex 1IBA
01/2014
1Sirolimus (Rapamycin)FDA Link
01/2014
1Interleukin-13IBA
10/2010
1OvalbuminIBA
07/2003
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
07/2003
1Interleukin-15 (Interleukin 15)IBA
01/2003
1Immunoglobulin G (IgG)IBA
01/2003
1Interleukin-2 Receptor alpha SubunitIBA
01/2003

Therapy/Procedure

4Immunotherapy
10/2022 - 05/2011
4Therapeutics
10/2022 - 05/2014
1Transplantation
11/2018
1Bone Marrow Transplantation (Transplantation, Bone Marrow)
05/2014
1Hematopoietic Stem Cell Transplantation
05/2014